Innovator 2015 - Summer Edition: A Breath of Hope for Patients with IPF
Dr. Martin Kolb & Dr. Gerard Cox measure a patient's lung capacity.
Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that has a higher mortality rate than cancer. The disease results in irreversible lung scarring that makes it difficult for patients to breathe properly. It is estimated that between 10,000-12,000 Canadians are diagnosed with IPF, and half of these patients will only live with the disease for an average of three to four years. Currently, the disease has no known cure.
Over the past few years, our researchers have led international studies that have proven the effectiveness of two new drugs in slowing down the progression of IPF. One of the drugs has now become available for Canadians and is covered by the Ontario Drug Benefit Program, while the other is currently undergoing approval.
To test the effectiveness of these drugs, Dr. Martin Kolb & Dr. Gerard Cox at St. Joe’s conduct clinical trials in collaboration with scientists and clinicians in over 30 countries around the world.
By working to prove the safety and effectiveness of new treatments, our researchers offer the hope of a longer life for those diagnosed with IPF. Dr. Kolb and Dr. Cox strive towards better treatments and the possibility of a cure for IPF and related lung diseases in the future.